ANAGENICS

ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – Cleansing Notice under section 708A(5)(e) of the Corporations Act

SYDNEY, Thursday, 12 October 2023

Anagenics Limited (ASX: AN1) (**Anagenics** or the **Company**), issued 13,157,895 fully paid ordinary shares (**Shares**) to the vendors of Face Medi Group on 11 October 2023 as set out in the Appendix 2A dated today.

This notice is being given under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) and the Company advises that:

- 1. The Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
- 2. As at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they may apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act; and
- 3. As at the date of this notice there is no information that is "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

Approved for release by the Board of Directors of Anagenics Limited.

Investor Enquiries:

Sandy Beard Chairman +61 412 308 263 info@anagenics.com

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated antiaging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. Advangen Pty Ltd is Anagenics' wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body. For further information, please see <u>www.anagenics.com</u> and <u>www.evolisproducts.com.au</u>.